[Oral melphalan plus high-dose dexamethasone as first-line therapy for patients with primary light chain amyloidosis].
Zhonghua Xue Ye Xue Za Zhi
; 39(8): 641-644, 2018 Aug 14.
Article
in Zh
| MEDLINE
| ID: mdl-30180464
ABSTRACT
Objective:
To evaluate the response of oral melphalan plus high-dose dexamethasone (MDex) for patients with primary light chain amyloidosis (pAL).Methods:
Clinical data, hematological and organ responses, and survival of 76 patients with pAL who had received MDex from January 2009 to July 2017 were retrospectively analyzed.Results:
Of 76 patients (47 males and 29 females with the median age of 56 [range, 20-74] years old), 19.70% patients were defined as Mayo 2004 stage 3, involvement of more than or two organs was presented in 65 (85.53%) patients. Among 60 response evaluable patients, overall hematological response was 48.33% with complete response of 20.00% and very good partial response of 20.00%, respectively. The median time to the hematological response was 5 (range, 1-15) months. 36.67% patients achieved organ response. After the median follow up of 23(range, 1-113) months for surviving patients, median progression-free survival (PFS) and overall survival (OS) were 34 and 43 months, respectively. In a three months landmark analysis, the median rates of PFS and OS were 46 and 65 months, respectively. The median OS rates of patients with Mayo 2004 stage 3 and non Mayo 2004 stage 3 were 5 and 65 months (P=0.001), respectively.Conclusions:
MDex was an effective treatment for patients with early stage pAL, but was not suitable for those with severe cardiac involvement.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Amyloidosis
Type of study:
Observational_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
Zh
Journal:
Zhonghua Xue Ye Xue Za Zhi
Year:
2018
Document type:
Article
Affiliation country:
China